Frankfurt - Delayed Quote ? EUR IN8bio, Inc. (6JH.F) Follow Compare 0.2960 -0.0340 (-10.30%) As of 3:29 PM GMT+1. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming poster presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, being hosted December 7 – 10, 2024 in San Diego, CA. Details for the ASH 2024 presentation are as follows: Title: INB-100: Pilot Study of Donor Derived, ex-vivo Expanded/Activated Gamma-Delta T cell Infus GlobeNewswire ? 2 days ago INAB INAB: Restructuring Narrows Focus to AML By John Vandermosten, CFA NASDAQ:INAB READ THE FULL INAB RESEARCH REPORT IN8bio, Inc (NASDAQ:INAB) announced a restructuring in a September 4th press release indicating that the company will focus on the INB-100 program for acute myeloid leukemia (AML). Due to the difficult financing environment and investor lack of interest in pursuing a glioblastoma multiforme (GBM) program, IN8bio has decided Zacks Small Cap Research ? last month INAB IN8bio Announces Pricing of $12.4 Million Private Placement Cash position now expected to fund current operating plan into 2026 Financing provides cash runway to advance the ongoing expansion cohorts in the Phase 1 trial of INB-100 for patients with Acute Myeloid Leukemia (AML) NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that it has entered into a definitive securities purchase agreement with accredited inves GlobeNewswire ? last month INAB IN8bio cuts staff and pipeline to focus on AML cell therapy The company has reduced its headcount by about 49% and suspended enrolment in a Phase II glioblastoma trial. Pharmaceutical Technology ? 2 months ago INAB IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia Top Priority Clinical Program: Working to drive significant value creation with INB-100 for AML; ongoing trial is actively enrolling additional patients into the expansion cohort to further support the observed 100% progression-free survival in AML patients as of August 30, 2024. Suspending enrollment of Phase 2 clinical trial of INB-400 in newly diagnosed GBM; will continue to monitor patients for long-term remissions and overall survival in both INB-400 and INB-200 at UAB.Company to preserve i GlobeNewswire ? 2 months ago INAB IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference NEW YORK, Aug. 29, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will be presenting at the: H.C. Wainwright 26th Annual Global Investment ConferenceFormat Fireside ChatDate/Time Monday, September 9, 2024, at 2:30 p.m. ET. A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section o GlobeNewswire ? 2 months ago INAB INAB: AML & GBM Clinical Update By John Vandermosten, CFA NASDAQ:INAB READ THE FULL INAB RESEARCH REPORT IN8bio, Inc (NASDAQ:INAB) reported second quarter 2024 financial results and achievements on August 8th followed a few days later by an update on the INB-100 and INB-200 programs and the anticipated path forward. In addition to showing continued impressive survival duration, IN8bio also shared the anticipated registrational Zacks Small Cap Research ? 2 months ago INAB IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100 Received FDA guidance on the registrational path for INB-100 in acute myeloid leukemia (AML), an investigational allogeneic gamma-delta T cell therapy, with IND submission anticipated in Q1 2025. Early clinical data from investigator sponsored trials demonstrates prolonged relapse-free survival across both AML and glioblastoma (GBM) programs, compared to current standard-of-care, with both programs advancing to Phase 2 clinical development. Solidifying position as a leader in gamma-delta T cell GlobeNewswire ? 2 months ago INAB IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights - Presented positive Phase 1 data showing 100% 1-year complete remission (CR) in evaluable patients with hematologic malignancies including acute myelogenous leukemia (AML) for INB-100 at the European Hematology Association (EHA) 2024 Congress - Continues to be an industry leader in the manufacturing and the clinical advancement of gamma-delta T cells for the treatment of solid and hematologic cancers - Demonstrated robust and reproducible manufacturing platform for DeltEx gamma-delta T cells hi GlobeNewswire ? 2 months ago INAB IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and Co-founder, will participate in a fireside chat during the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024 at 2:30 p.m. ET. A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of GlobeNewswire ? 4 months ago INAB INAB: INB-100 Update at EHA24 ?Olé! By John Vandermosten, CFA NASDAQ:INAB READ THE FULL INAB RESEARCH REPORT IN8bio, Inc (NASDAQ:INAB) presented updated results from its Phase I INB-100 trial at the European Hematology Association (EHA) Congress on June 13th in Madrid, Spain. Details of the presentation were provided in a press release and conference call after the close on June 13th, 2024 along with a slide deck to guide the Zacks Small Cap Research ? 4 months ago INAB IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 100% of treated leukemia patients (n=10/10) achieved durable complete remission (CR) at 1-year, including high-risk and relapsed acute myeloid leukemia (AML) patients who had previously failed multiple lines of therapy, including CAR-T. Data continue to show long-term in vivo expansion and persistence of allogeneic gamma-delta T cells 365 days following a single administration, demonstrating first-ever durable persistence and expansion of an allogeneic cellular therapy. The Company will host a c GlobeNewswire ? 4 months ago INAB INAB: INB-200 Update at ASCO24 By John Vandermosten, CFA NASDAQ:INAB READ THE FULL INAB RESEARCH REPORT IN8bio, Inc (NASDAQ:INAB) updated results from its Phase I INB-200 clinical trial at the American Society of Clinical Oncology (ASCO) 2024 meeting last Saturday. Sponsored by the University of Alabama, the trial is evaluating the use of γδ T cell therapy for treatment of patients with newly diagnosed glioblastoma (GBM). As Zacks Small Cap Research ? 5 months ago INAB IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting 92% of evaluable patients treated with INB-200 for glioblastoma exceeded a median progression-free survival (PFS) of seven months achieved with the standard-of-care regimen (Stupp regimen) Majority of fully dosed patients exceeded the expected median PFS based on age and tumor status; one patient from Cohort 2 remains alive and progression free at almost three years Radiologic evaluation indicative of “treatment effect” including changes in MRI enhancement and resolution of mid-line shift NEW YO GlobeNewswire ? 5 months ago INAB IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024 NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced multiple presentations at the International Society for Cell & Gene Therapy 2024, to be held May 28th to June 1st in Vancouver, Canada. “ISCT is a scientific gathering renowned for fostering groundbreaking ideas and innovation in cellular therapies,” said Dr. Kate Rochlin, Chief Operating Officer of IN8bio. “Our pres GlobeNewswire ? 5 months ago INAB IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming presentation of updated results from its fully enrolled Phase 1 study of INB-200 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 31st - June 4th in Chicago, Illinois. INB-200 is evaluating autologous Drug Resistant Immunotherapy (DeltEx DRI) or chemotherapy resistan GlobeNewswire ? 5 months ago INAB INAB: 1Q:24 Results By John Vandermosten, CFA NASDAQ:INAB READ THE FULL INAB RESEARCH REPORT IN8bio, Inc (NASDAQ:INAB) reported first quarter 2024 financial results and achievements on May 9th. Since our initiation last month, the company has dosed its first patient in the INB-400 trial and presented technical details of its manufacturing at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Zacks Small Cap Research ? 5 months ago INAB IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, announced today a presentation at the European Hematology Association 2024 Congress, to be held June 13-16 in Madrid, Spain. “We’re excited to share the latest updated interim results from our Phase 1 trial evaluating our gamma-delta T cell therapy INB-100 after haploidentical stem cell transplantation for patients with leukemia at GlobeNewswire ? 5 months ago INAB IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024 NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell therapies, presented in an oral session details about its robust and reproducible proprietary clinical-scale gamma-delta T cell manufacturing platform across different donor populations, at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting. In an oral presentation titled: “Healthy Donor vs. Patient Manufactured Autologous DeltE GlobeNewswire ? 5 months ago INAB IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights - Presented new preclinical data demonstrating proof-of-concept for non-signaling Chimeric Antigen Receptor (nsCAR) platform to effectively target cancer cells while preserving healthy tissue - Demonstrated potential of nsCAR platform to treat previously “undruggable” solid and liquid tumor targets - Announced peer-reviewed publication in ‘Frontiers in Immunology’ on IN8bio’s DeltEx Drug Resistant Immunotherapy (DRI) approach to newly diagnosed glioblastoma multiforme (GBM) - Dosed first patient GlobeNewswire ? 5 months ago INAB Performance Overview Trailing total returns as of 11/7/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return 6JH.F S&P 500 YTD -76.51% +25.17% 1-Year -68.84% +36.75% 3-Year -92.53% +24.56%
